Status:
COMPLETED
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
Lead Sponsor:
Pfizer
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection. Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the ...
Eligibility Criteria
Inclusion
- Males or females, without evidence of infection with HIV,HBV or HCV, who are on chronic methadone maintenance for at least three months and at a stable dose for at least 1 week prior to study start.
Exclusion
- Evidence of chronic diseases including HIV, HBV or HCV.
- Evidence of acute or chronic liver disease.
- Treatment with prescription or nonprescription drugs other than methadone within 7 days.
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01210404
Start Date
February 1 2011
End Date
June 1 2011
Last Update
June 7 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Overland Park, Kansas, United States, 66211
2
Pfizer Investigational Site
Overland Park, Kansas, United States, 66212